Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Taro Pharmaceutical Industries Ltd.    TARO   IL0010827181

News SummaryMost relevantAll newsSector newsTweets 

Taro Pharmaceutical Industries Ltd. : Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

share with twitter share with LinkedIn share with facebook
share via e-mail
11/08/2012 | 11:25pm CET

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it delivered a letter to one of its shareholders IsZo Capital Management LP ("IsZo") in response to IsZo's letter to Taro's Special Committee of the Board of Directors dated November 5, 2012. The full text of the letter is set forth below:

Re: Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

Dear Mr. Sheehy,

We at Taro are very appreciative of our shareholders' communications. More recently, our ability to respond to certain inquiries has been limited in light of the pending merger between Taro and Sun Pharma and the related shareholder meeting scheduled December 6, 2012. Rather, our management team's primary focus continues to be on Taro's core business, the performance of which speaks for itself.

Without responding to your many unfounded allegations over the past few months, I feel compelled to publicly correct one of your most recent statements. In your November 5th letter and corresponding press release, you contend that Taro is "gaming its reserves." Your allegation is simply untrue and your comment is, at a minimum, irresponsible to your fellow Taro shareholders.

As a NYSE listed company, Taro takes its financial accounting and reporting obligations very seriously. Although our quarterly financial reporting is presented on an unaudited basis, the accounting methodologies used in estimating our reserves are "consistently applied" quarter to quarter, in conformity with U.S. GAAP. Over the last couple of years, at the request of our Board and Audit Committee, we have taken an extra step by having our independent auditors perform certain "agreed upon procedures" on our financial statements focusing on specific areas, including reserves, prior to issuing our quarterly releases, including that for the quarter ended September 30, 2012.

Given your broad industry knowledge, you undoubtedly appreciate that, while IMS data is useful to the industry for general U.S. market intelligence and a general understanding of long term, product trends, it is not reliable (or prepared) for consolidated financial reporting analysis as you propose.

Finally, I recognize your excitement for Taro as expressed in your letter. I believe that all Taro shareholders have benefited tremendously at what the new management team, under the leadership of Mr. Shanghvi and, subsequently, Mr. Sundaram, have accomplished since the change in control in September 2010.


/s/ Jim Kedrowski

Jim Kedrowski
Interim Chief Executive Officer


About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
02/09 TARO PHARMACEUTICAL INDUSTRIES : Provides Results for December 31, 2016
02/09 TARO PHARMACEUTICAL INDUSTRIES : to Announce Third Quarter Results on February 9..
01/31 TARO PHARMACEUTICAL INDUSTRIES : to Announce Third Quarter Results on February 9..
01/06 TARO PHARMACEUTICAL INDUSTRIES : Announces Sale of U.S. Rights to Keveyis® to St..
01/02 TARO PHARMACEUTICAL INDUSTRIES : Of hawthorne sells drug rights
2016 TARO PHARMACEUTICAL INDUSTRIES : GPM Reminds Investors of the December 27th Dead..
2016 TARO PHARMACEUTICAL INDUSTRIES : Strongbridge Biopharma plc Announces Acquisitio..
2016 TARO 72 HOUR DEADLINE ALERT : Approximately 72 Hours Remain; Former Louisiana At..
2016 Levi & Korsinsky, LLP Reminds Shareholders of Taro Pharmaceutical Industries ..
More news
Sector news : Pharmaceuticals - NEC
10:23aDJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
08:49aDJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
08:49aDJBAYER : CEO Still Upbeat on Deal -- WSJ
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/22DJBAYER : Details Financing Plan for Monsanto Deal
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/09 Taro Pharmaceutical reports FQ3 results
01/20 Teva's Got Potential - And The Complexity To Go With It
01/20 Would You Buy Secretive Taro Pharmaceutical Based On The Track Record Of Indi..
2016 TEVA : Is It Cheap Enough?
2016 Strongbridge Biopharma acquires U.S. rights to KEVEYIS from Taro Pharmaceutic..
Financials ($)
Sales 2017 902 M
EBIT 2017 550 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 10,47
P/E ratio 2018 11,47
Capi. / Sales 2017 5,24x
Capi. / Sales 2018 5,63x
Capitalization 4 726 M
More Financials
Duration : Period :
Taro Pharmaceutical Indust Technical Analysis Chart | TARO | IL0010827181 | 4-Traders
Full-screen chart
Technical analysis trends TARO PHARMACEUTIC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 135 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Abhay Gandhi Chief Executive Officer & Director
Dilip Shantilal Shanghvi Chairman
Itamar Karsenti Vice President & Operations Head-Haifa
Mariano Balaguer VP, Chief Financial & Accounting Officer
Avi Avramoff Global Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.86%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.51%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.11.23%180 014
More Results